HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Kenton J. Zehr Peter W. Cho William A. Baumgartner Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uthoff, K. Articles by Stuart, R. S. Search for Related Content PubMed PubMed Citation Articles by Uthoff, K. Articles by Stuart, R. S.

Ann Thorac Surg 1995;59:277-282
© 1995 The Society of Thoracic Surgeons

Thalidomide as Replacement for Steroids in Immunosuppression After Lung Transplantation

Division of Cardiac Surgery and Departments of Pathology and Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland

Steroids have been implicated in postoperative complications after lung transplantation: infections, delayed wound healing, and poor bronchial anastomotic healing. Thalidomide (-phthalimidoglutarimide), a sedative drug with known immunomodulatory properties, was used to replace corticosteroids after canine lung transplantation. Fifteen mongrel dogs underwent single-lung transplantation: group I (n = 5) received cyclosporin A (20 mg/kg twice a day), azathioprine (2.5 mg/kg once a day), and thalidomide (50 mg/kg twice a day). Group II (n = 5) received standard immunosuppression of cyclosporin A (20 mg/kg twice a day), azathioprine (2.5 mg/kg once a day), and prednisone (2 mg/kg once a day), and group III (n = 5) received cyclosporin A (10 mg/kg twice a day), azathioprine (2.5 mg/kg once a day), and thalidomide (50 mg/kg twice a day). Open lung biopsy and bronchoscopy were performed weekly until sacrifice on day 28. Serum thalidomide and cyclosporin A levels were followed up weekly. Group I showed essentially no rejection until week 2 and minimal rejection (grade 1) until day 28. Group II had moderate rejection (grade 2) of the graft at all time points. Group III animals had moderate to severe rejection (grades 3 to 4) after 21 days (p < 0.05 for group I versus groups II and III). The number of clinically evident episodes of pneumonia was also significantly lower in group I than in groups II and III (p < 0.05). We conclude that thalidomide appears to replace corticosteroids effectively in early postoperative immunosuppression after lung transplantation and is associated with a decreased incidence of pneumonia. It was not efficacious in combination with low-dose cyclosporin A. This drug may have a significant impact after clinical lung transplantation by reducing steroid-associated complications.

This article has been cited by other articles:

				Q. Ye, B. Chen, Z. Tong, S. Nakamura, R. Sarria, U. Costabel, and J. Guzman Thalidomide reduces IL-18, IL-8 and TNF-{alpha} release from alveolar macrophages in interstitial lung disease Eur. Respir. J., October 1, 2006; 28(4): 824 - 831. [Abstract] [Full Text] [PDF]

				M. R Nasca, G. Micali, N. H Cheigh, L. E West, and D. P West Dermatologic and Nondermatologic Uses of Thalidomide Ann. Pharmacother., September 1, 2003; 37(9): 1307 - 1320. [Abstract] [Full Text] [PDF]

				R. P. Baughman, M. A. Judson, A. S. Teirstein, D. R. Moller, and E. E. Lower Thalidomide for Chronic Sarcoidosis* Chest, July 1, 2002; 122(1): 227 - 232. [Abstract] [Full Text] [PDF]